Systematic Reviews
Copyright ©The Author(s) 2020.
World J Gastroenterol. Jan 21, 2020; 26(3): 353-365
Published online Jan 21, 2020. doi: 10.3748/wjg.v26.i3.353
Table 2 Baseline characteristics of cases of programmed cell death-1 inhibitor-related sclerosing cholangitis
CaseRef.AgeSexPrimary diseaseDrugCycles until onsetSymptoms
1Gelsomino et al[21]79MNSCLCNivolumab4Itching, jaundice
2Kawakami et al[19]64MNSCLCNivolumab9Fever, abdominal discomfort
3Kawakami et al[19]73FNSCLCNivolumab6Fever, vomiting, abdominal discomfort, diarrhea
4Kawakami et al[19]82FNSCLCNivolumab12Fever, general fatigue
5Kashima et al[22]63MNSCLCNivolumab24Epigastric pain, soft stool
6Doherty et al[23]49FMelanomaPembrolizumab1Jaundice
7Doherty et al[23]59FMelanomaNivolumab3None (liver dysfunction)
8Doherty et al[23]76Mepithelioid mesotheliomaPembrolizumab1Jaundice
9Cho et al[24]69MNSCLCAvelumab21Right upper abdominal discomfort
10Hamoir et al[25]71MNSCLCNivolumabNA (11 mo)None (liver dysfunction)
11Kuraoka et al[26]69MNSCLCNivolumab3Pruritic rash, liver dysfunction
12Ogawa et al[27]73MMelanomaPembrolizumabNA (3 mo)None (liver dysfunction)
13Kono et al[28]69FGCNivolumab2Jaundice
14Noda-Narita et al[29]57FNSCLCNivolumabNA (12 mo)Abdominal pain
15Sawada et al[30]76MGCNivolumab4None (liver dysfunction)
16Tallec et al[31]56FNSCLCNivolumab16 (9 mo)Myalgia, skin thickening
17Oda et al[32]43MGCNivolumab1Fever, tachycardia, appetite loss, malaise
18Koya et al[33]66MSCLCPembrolizumab5Epigastric pain
19Fouchard et al[34]52MNSCLCNivolumab8Abdominal pain
20Fouchard et al[34]NAMNSCLCDurvalumab (+ tremelimumab)4Fever, abdominal pain
21Fouchard et al[34]61MNSCLCPembrolizumab17None (liver dysfunction)
22Cǎlugǎreanu et al[35]43FMelanomaNivolumab27Epigastralgia, anorexia,
23Anderson et al[36]67MNSCLCNivolumab8Right upper abdominal pain
24Zen et al[37]68MNSCLCPembrolizumabNA (5.5 mo)Abdominal pain, vomiting
25Zen et al[40]67MNSCLCPembrolizumabNA (1 mo)Fever, malaise
26Our case61MBCPembrolizumab5Fever
27Our case89MBCPembrolizumab4None (liver dysfunction)
28Our case63MNSCLCPembrolizumab7None (liver dysfunction)
29Our case55MNSCLCNivolumab11Abdominal pain
30Our case81FNSCLCNivolumab25Backache
31Our case82FNSCLCNivolumab2None (liver dysfunction)